Drugs / ABN401
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05248074 | Jan → Feb 2022 | cancer | Abion Inc | Completed | No outcome recorded |
| Phase 1 | NCT04052971 | Aug 2019 → Nov 2023 | cancer | Abion Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05882292 | Nov 2023 → Dec 2025 overdue | neoplasm | Yonsei University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABN401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05248074 ↗ |
| Action | Inhibit | “ABN401 competitively attaches to the ATP binding sites in the kinase domain of c-MET with high specificity to inhibit phosphorylation of downstream signaling pathways.” NCT05882292 ↗ |
| Route | Oral | “Route of Administration: Oral” NCT04052971 ↗ |
| Target | MET | “ABN401 competitively attaches to the ATP binding sites in the kinase domain of c-MET with high specificity to inhibit phosphorylation of downstream signaling pathways.” NCT05882292 ↗ |